Brought to you by 
CoTherix licenses rights to Ventavis from Schering AG
02 Jun 2009
Executive Summary
Pulmonary therapeutics company CoTherix has licensed exclusive US development and marketing rights from Schering AG to Ventavis, a treatment for primary pulmonary hypertension.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CoTherix licenses rights to Ventavis from Schering AG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice